[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356296-105":59,"doc-detail-356296-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","circulating-spd-l1-as-a-tumor-microenvironment-derived-biomarker-enhancing-diagnostic-discrimination-accuracy-in-breast-cancer","Circulating sPD-L1 as a tumor microenvironment-derived biomarker - enhancing diagnostic discrimination accuracy in breast cancer","","Circulating soluble PD-L1 (sPD-L1) is evaluated as a non-invasive biomarker for tumor microenvironment (TME) assessment and breast cancer diagnosis. Serum sPD-L1 levels are measured in healthy and breast-affected populations, then correlated with inflammatory markers and clinicopathological features. Diagnostic discrimination is quantified by ROC curve analysis against conventional biomarkers including CEA and CA15-3. Cellular-level mechanisms are explored by quantifying sPD-L1 and IL-6 in culture supernatants, with PBMC co-culture experiments showing coordinated induction validated clinically by serum sPD-L1/IL-6 correlation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-spd-l1-as-a-tumor-microenvironment-derived-biomarker-enhancing-diagnostic-discrimination-accuracy-in-breast-cancer/356296/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-spd-l1-as-a-tumor-microenvironment-derived-biomarker-enhancing-diagnostic-discrimination-accuracy-in-breast-cancer/356296.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is tissue-based PD-L1 detection considered limited for breast cancer?","Question",{"text":113,"@type":114},"Tissue testing is constrained by spatial heterogeneity, dynamic expression changes, and the invasiveness of repeated biopsies, which reduce its practicality as a reliable biomarker.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the study assess diagnostic discrimination performance of sPD-L1?",{"text":118,"@type":114},"It uses receiver operating characteristic (ROC) curve analysis to compare sPD-L1 with conventional biomarkers and determine an optimal diagnostic cut-off.",{"name":120,"@type":111,"acceptedAnswer":121},"What mechanism link does the study investigate between sPD-L1 and tumor immunity?",{"text":122,"@type":114},"The work examines cellular-level interactions by measuring sPD-L1 and IL-6 secretion in culture supernatants, and validates a coordinated sPD-L1/IL-6 relationship through serum correlation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356296,1790609892,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Immunology, Immunotherapy (2026) 75:63  \n[https://doi.org/10.1007/s00262-026-04309-y](https://doi.org/10.1007/s00262-026-04309-y)  \nCirculating sPD‑L1 as a tumor microenvironment‑derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer  \nYue Zhang1 · Shuyi Chen1 · Jie Ma2 · Xinchen Sun1 · Xiaobin Zhou1  \nReceived: 3 September 2025 / Accepted: 13 January 2026 © The Author(s) 2026  \nAbstract  \nProgrammed cell death ligand 1 (PD-L1) plays a pivotal role in breast cancer immune evasion, yet tissue-based detection suffers from invasiveness and spatial heterogeneity. This study investigated circulating soluble PD-L1 (sPD-L1) as a non-invasive alternative for tumor microenvironment (TME) assessment and breast cancer diagnosis. Serum sPD-L1 levels were evaluated in healthy and breast-affected populations, with correlations assessed against inflammatory markers and clinicopathological parameters. Diagnostic performance of sPD-L1 was compared to conventional biomarkers using receiver operating characteristic (ROC) curve analysis. Cellular-level interactions were investigated by quantifying sPD-L1 and interleukin-6 (IL-6) in culture supernatants. Circulating sPD-L1 expression was significantly elevated in breast cancer versus healthy controlsand benign cases, with notably higher levels observed in advanced stages and distant-metastatic cases. Moderate correlations were observed between serum sPD-L1 and various inflammatory indicators. Specifically, ROC curve analysis identified an optimal diagnostic cut-off value of 1.144 ng/mL for sPD-L1, with its discriminative power outperforming conventional biomarkers such as CEA and CA15-3 . In vitro, peripheral blood mononuclear cells (PBMCs) co-cultured with breast cancer cells showed enhanced sPD-L1 and IL-6 secretion versus normal epithelial cell co-cultures, with parallel sPD-L1/IL-6 elevation. This coordinated induction was clinically validated by a positive serum sPD-L1/IL-6 correlation. In conclusion, circulating sPD-L1 represents a promising non-invasive biomarker reflecting TME and disease progression, supporting its potential utility for breast cancer diagnostic discrimination.  \nKeywords sPD-L1 · Biomarker · Cancer diagnosis · Tumor immunity · Breast cancer  \nAbbreviations  \nAUC Area under the curve  \nBBD Benign breast disease  \nBC Breast cancer  \nCEA Carcinoembryonic antigen CA15-3 Glycoconjugate antigen 15–3 CI Confidence interval  \nCA125 Glycoconjugate antigen 125 HD Healthy donors  \n* Yue Zhang [yue_zhang@aa.seu.edu.cn](yue_zhang@aa.seu.edu.cn)  \n* Xiaobin Zhou [shoppingchow@sina.com](shoppingchow@sina.com)  \n1 Clinical Medical Laboratory Center, Gaogang Branch, Taizhou School of Clinical Medicine, Nanjing Medical University, The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou 225300, China  \n2 Clinical Laboratory Department, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China  \nIL-6  \nLMR  \nNETs  \nNLR  \nNC  \nOR  \nPD-L1  \nPD-1  \nPBMCs  \nPLR  \nROS  \nROC  \nsiRNA  \nTME  \nWBC  \nInterleukin-6  \nLymphocyte-to-monocyte ratio Neutrophil extracellular traps Neutrophil-to-lymphocyte ratio Negative control  \nOdds ratio  \nProgrammed cell death ligand 1 Programmed cell death protein 1 Peripheral blood mononuclear cells Platelet-to-lymphocyte ratio Reactive oxygen species Receiver operating characteristic Small interfering RNA  \nTumor microenvironment White blood cell  \nIntroduction  \nBreast cancer remains the most frequently diagnosed malignancy in women, with rising global incidence rates and maintaining its position as the primary cause of cancer-related female mortality [1] . The implementation of early screening programs and accurate diagnostic approaches enables timely therapeutic interventions that significantly improve survival outcomes and quality of life in affected patients.  \nThe tumor microenvironment (TME) constitutes a highly structured ecosystem comprising diverse immune cells, soluble mediators","cbCaifqUTmJCmvn0","https://ap.wps.com/l/cbCaifqUTmJCmvn0","pdf",2176329,13,"English","# Abstract\n## Introduction\n### Rationale for TME and PD-L1\n### Limitations of tissue-based PD-L1 testing\n### Rationale for circulating sPD-L1 and comparison biomarkers","[{\"question\":\"Why is tissue-based PD-L1 detection considered limited for breast cancer?\",\"answer\":\"Tissue testing is constrained by spatial heterogeneity, dynamic expression changes, and the invasiveness of repeated biopsies, which reduce its practicality as a reliable biomarker.\"},{\"question\":\"How does the study assess diagnostic discrimination performance of sPD-L1?\",\"answer\":\"It uses receiver operating characteristic (ROC) curve analysis to compare sPD-L1 with conventional biomarkers and determine an optimal diagnostic cut-off.\"},{\"question\":\"What mechanism link does the study investigate between sPD-L1 and tumor immunity?\",\"answer\":\"The work examines cellular-level interactions by measuring sPD-L1 and IL-6 secretion in culture supernatants, and validates a coordinated sPD-L1/IL-6 relationship through serum correlation.\"}]","Circulating sPD-L1 as a tumor microenvironment-derived biomarker - enhancing diagnostic discrimination accuracy in breast cancer | PDF",1790124480,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b1904f38a5302b46a957ff3f028bffc.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/043c594328f24bb27a269dd3989a0de9.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6cbe368ce7c9f664286b365d42d7077.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a581a0df759605c704e72d411563c24.webp",980,1301]